Otamixaban

Jump to: navigation, search

{{Drugbox | Verifiedfields = changed | verifiedrevid = 462266309 | IUPAC_name = Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | image = Otamixaban.png | image2 = Otamixaban 3D.png

| tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ☒N | CAS_number = 193153-04-7 | ATC_prefix = none | ATC_suffix = | PubChem = 5496659 | DrugBank_Ref =  ☑Y | DrugBank = | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4593439 | UNII_Ref =  ☑Y | UNII = S173RED00L | ChEMBL_Ref =  ☑Y | ChEMBL = 46618

| C=25 | H=26 | N=4 | O=4 | molecular_weight = 446.498 g/mol | smiles = O=C(OC)[C@H](Cc1cc(C(=[N@H])N)ccc1)[C@H](NC(=O)c3ccc(c2cc[n+]([O-])cc2)cc3)C | InChI = 1/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 | InChIKey = PFGVNLZDWRZPJW-OPAMFIHVBD | StdInChI_Ref =  ☑Y | StdInChI = 1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1 | StdInChIKey_Ref =  ☑Y | StdInChIKey = PFGVNLZDWRZPJW-OPAMFIHVSA-N }}

WikiDoc Resources for Otamixaban

Articles

Most recent articles on Otamixaban

Most cited articles on Otamixaban

Review articles on Otamixaban

Articles on Otamixaban in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Otamixaban

Images of Otamixaban

Photos of Otamixaban

Podcasts & MP3s on Otamixaban

Videos on Otamixaban

Evidence Based Medicine

Cochrane Collaboration on Otamixaban

Bandolier on Otamixaban

TRIP on Otamixaban

Clinical Trials

Ongoing Trials on Otamixaban at Clinical Trials.gov

Trial results on Otamixaban

Clinical Trials on Otamixaban at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Otamixaban

NICE Guidance on Otamixaban

NHS PRODIGY Guidance

FDA on Otamixaban

CDC on Otamixaban

Books

Books on Otamixaban

News

Otamixaban in the news

Be alerted to news on Otamixaban

News trends on Otamixaban

Commentary

Blogs on Otamixaban

Definitions

Definitions of Otamixaban

Patient Resources / Community

Patient resources on Otamixaban

Discussion groups on Otamixaban

Patient Handouts on Otamixaban

Directions to Hospitals Treating Otamixaban

Risk calculators and risk factors for Otamixaban

Healthcare Provider Resources

Symptoms of Otamixaban

Causes & Risk Factors for Otamixaban

Diagnostic studies for Otamixaban

Treatment of Otamixaban

Continuing Medical Education (CME)

CME Programs on Otamixaban

International

Otamixaban en Espanol

Otamixaban en Francais

Business

Otamixaban in the Marketplace

Patents on Otamixaban

Experimental / Informatics

List of terms related to Otamixaban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Otamixaban (INN) is an experimental injectable anticoagulant direct factor Xa inhibitor,[1] that was investigated for the treatment for acute coronary syndrome. In 2013, Sanofi announced that it had ended development of the drug candidate after poor performance in a Phase III clinical trial.[2][3]

References

  1. Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID 17979700.
  2. "AstraZeneca, Sanofi Cut Programs". Chemical & Engineering News. American Chemical Society. 91 (23): 17. June 10, 2013. Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies.
  3. "Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs". RTT news. Retrieved 11 April 2014.

Linked-in.jpg